Who Paid My Doc Search
Menu
Organisation paid for research Program year 2023 Source: CMS Open Payments

Adly Thebaud MD PA

Neither a doctor nor a teaching hospital

Research payments

$518,521

176 payments

Through program year 2023, Adly Thebaud MD PA is reported as receiving $518,521 in research payments, across 176 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $12,764 2
2022 Research $16,388 18
2021 Research $105,541 29
2020 Research $182,816 76
2019 Research $201,011 51

Breakdown

Who paid Research payments · program years 2019–2023
  1. ITI, Inc. $101,632 19 payments
  2. F. Hoffmann-La Roche AG $98,048 83 payments
  3. Otsuka Pharmaceutical Development & Commercialization, Inc. $91,317 2 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $74,725 7 payments
  5. H. Lundbeck A S $55,974 11 payments
  6. Pfizer Inc. $18,243 9 payments
  7. Sunovion Pharmaceuticals Inc. $15,225 2 payments
  8. Eisai Inc. $12,689 7 payments
  9. AbbVie, Inc. $10,165 16 payments
  10. Shire North American Group Inc $10,035 7 payments
Studies the money was for Research payments · program years 2019–2023
  1. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression) or Major Depressive Disorder $100,532 17 payments
  2. V1a 2 in Pediatric Autism $98,048 83 payments
  3. A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Trial Evaluating the Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficithyperactivity Disorder Trial 405-201-00014 $79,368 1 payment
  4. FEP CHR PoC $74,636 6 payments
  5. Active Reference (Fluoxetine) Fixed-Dose Study of Vortioxetine in Pediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD) $37,574 9 payments
  6. Vortioxetine to Prevent Return of Symptoms in Children With Depression $18,400 2 payments
  7. A Phase 3 Multicenter Fourweek Randomized Doubleblind Placebocontrolled Parallelgroup Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder Current Or Most Recent Episode Manic $18,243 9 payments
  8. Pediatric Open-Label Extension Study $15,225 2 payments
  9. A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $12,689 7 payments
  10. An Open-Label, 52-Week, Multicenter Trial Evaluating the Long-Term Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficithyperactivity Disorder $11,949 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record